Repligen Corporation $RGEN Shares Sold by Baird Financial Group Inc.

Baird Financial Group Inc. cut its position in shares of Repligen Corporation (NASDAQ:RGEN) by 9.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 272,207 shares of the biotechnology company’s stock after selling 28,946 shares during the quarter. Baird Financial Group Inc. owned 0.48% of Repligen worth $33,857,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of RGEN. Twin Tree Management LP purchased a new stake in shares of Repligen during the 1st quarter worth about $29,000. Hantz Financial Services Inc. grew its holdings in Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares during the last quarter. Center for Financial Planning Inc. grew its holdings in Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 126 shares during the last quarter. AlphaQuest LLC acquired a new stake in shares of Repligen in the second quarter valued at about $104,000. Finally, Hilltop National Bank acquired a new position in shares of Repligen during the 2nd quarter worth about $147,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Repligen

In other Repligen news, COO James Bylund sold 2,191 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anthony Hunt sold 20,000 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the completion of the transaction, the director directly owned 80,743 shares of the company’s stock, valued at $12,483,675.23. This trade represents a 19.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 49,382 shares of company stock valued at $7,676,802 in the last ninety days. Insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on RGEN shares. Barclays raised their price target on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. HSBC initiated coverage on shares of Repligen in a research note on Wednesday, October 1st. They issued a “buy” rating and a $150.00 target price on the stock. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Finally, Canaccord Genuity Group increased their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $173.85.

Repligen Stock Down 0.5%

Shares of Repligen stock opened at $164.98 on Friday. The business has a fifty day simple moving average of $153.86 and a 200 day simple moving average of $133.11. The stock has a market cap of $9.29 billion, a PE ratio of 8,253.13, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The firm had revenue of $188.81 million for the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The company’s revenue was up 21.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Research analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.